Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.

Keywords

Gene duplication, Oncogene, INT, Breast cancer, Internal medicine

References

• Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.JM Varley, Julia Swallow, William J. Brammar — 1987
• The enhancing effect (or actively acquired tolerance) and the histocompatibility-2 locus in the mouse.George D. Snell — 1954
• Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.John A. Foekens, Henk Portengen, W L van Putten — 1989
• Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.Irene García, Pierre‐Yves Dietrich, Matti Aapro — 1989
• Follow-up study of HER-2/neu amplification in primary breast cancer.Gary M. Clark, William McGuire — 1991
• Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.M J Cline, Hector Battifora, Jun Yokota — 1987
• Chapter III. 1. Mutations in human breast cancer cells: Dominantly‐acting oncogenes and tumor suppressor genes suggest strategies for targeted interferenceBernd Groner, Nancy E. Hynes — 1990
• Potential oncogene product related to growth factorsClive Dickson, Gordon Peters — 1987
• A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.Andrew P. Feinberg, Bert Vogelstein — 1983
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesJulian Downward, Yosef Yarden, E. L. V. Mayes — 1984
• 4. The role of the epidermal growth factor receptor and the c‐erbB‐2 protein in breast cancerWilliam J. Gullick — 1990
• Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.Chantal Escot, Charles Theillet, Rosette Lidereau — 1986
• The neu oncogene encodes an epidermal growth factor receptor-related proteinCornelia I. Bargmann, Mien‐Chie Hung, Robert A. Weinberg — 1986
• Int-1 and int-2: oncogenic proteins, mitogens and morphogens?Antony W. Burgess — 1988
• c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.Manoochehr Tavassoli, Philip Quirke, Farzin Farzaneh — 1989
• Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.Jean‐Paul Brouillet, Charles Theillet, Thierry Maudelondé — 1990
• A paradigm for oncogene complementation in human breast cancer.Magali Roux-Dosseto, P.M. Martin — 1989
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.Alan L. Schechter, Mien‐Chie Hung, Lalitha Vaidyanathan — 1985
• Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.Shari Meyers, Meghan O’Brien, Terry Smith — 1990
• Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.Hitoshi Tsuda, S Hirohashi, Yukío Shimosato — 1989

Cited by

• ErbB-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors公雄 上松 — 1995
• Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values.Serge Koscielny, P. Terrier, A Daver — 1998
• The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors.Shaun R. Harper, Jerlando F. L. Jackson, Ann E. Austin — 2000
• HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, TrastuzumabSebastián Planas — 2002
• Critical review of growth factors as clinical tools in primary and metastatic breast cancer.J.G.M. Klijn, P.M.J.J. Berns, Wim L.J. van Putten — 1993
• 1+1=? Combinations and combination strategies in early cancer-drug developmentP. Hamberg — 2014
• Influence of c-myc on the progression of human breast cancer.Peter H. Watson, Rajinder Singh, A. Hole — 1996
• What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.H.J.S. Dawkins, Peter Robbins, Karen Smith — 1993
• Prognostic Significance of Loss-of-Heterozygosity of the CUTL1 Putative Tumor Suppressor Gene in Breast CancersA. Nepveu — 1998
• Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.Marcia Hall, Gordon Peters — 1996
• Understanding the Metabolic and Genetic Regulation of Breast Cancer Recurrence Using Magnetic Resonance-Based Integrative MetabolomicsD. Daye — 2012
• The Role of Amplified Wild-Type Neu in the Etiology of Breast CancerM. Gould — 2002
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profilingH. Horlings — 2011
• Potential for biomolecular imaging with femtosecond X-ray pulsesRichard Neutze, R. Wouts, David van der Spoel — 2000
• Significance of HER2 and C‐MYC oncogene amplifications in breast cancer in atomic bomb survivorsShiro Miura, Masahiro Nakashima, Masahiro Ito — 2008
• Tissue microarrays for gene amplification surveys in many different tumor types.Peter Schraml, Juha Kononen, Lukas Bubendorf — 1999
• Analysis of p53 and c-MYC, two key transcription factors involved in tumorigenesisPeter Jung — 2008
• Determination of c‐erbB‐2 Protein in Primary Breast Cancer Tissue Extract Using an Enzyme ImmunoassayToru Watanabe, Takashi Fukutomi, Hitoshi Tsuda — 1993
• Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenesAna M. Bajo, Andrew V. Schally, Magdalena Krupa — 2002
• Prognostic Factors and Proliferative Activities in Breast Cancer. A Comparative Study between Recurrent and Non-Recurrent Cases of Human Breast CarcinomasYoshiaki Imamura, Makoto Ishida, Kohjiro Horita — 1997

Related papers

• Dommages-intérêts, intérêt positif et intérêt négatifSylvain Ravenne — 2016
• Intérêt individuel, intérêt privé, intérêt commun - Les complications de la notion d’intérêt particulierBlaise Bachofen — 2014
• Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.Haeri Roh, James A. Pippin, Craig Boswell — 1998
• The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene.Jah-Yao Liu, Tzu‐Chao Chuang, Tzong‐Der Way — 2009